BTIG lowered the firm’s price target on Simulations Plus (SLP) to $25 from $41 and keeps a Buy rating on the shares following the firm’s survey of biopharma manufacturers. R&D Services budgets will likely face the most risk and headwinds over the next 2 years, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- Simulations Plus management to meet virtually with Craig Hallum
- Simulations Plus Reschedules Q3 2025 Earnings Release
- Simulations Plus price target lowered to $36 from $45 at Craig-Hallum
- Simulations Plus price target lowered to $28 from $42 at Stephens
- Closing Bell Movers: Oracle jumps 7% after Q4 earnings beat